Journal article
Soluble programmed death-1 (sPD-1) as predictor of early surgical outcomes of pediatric cystic echinococcosis.
- Ben Salah E Université de Monastir, Faculté de Pharmacie, Laboratoire de Parasitologie-Mycologie Médicale et Moléculaire, LR12ES08 Departement de Biologie clinique B, 5000, Monastir, Tunisie.
- Sakly W Université de Monastir, Faculté de Pharmacie, Laboratoire de Parasitologie-Mycologie Médicale et Moléculaire, LR12ES08 Departement de Biologie clinique B, 5000, Monastir, Tunisie.
- Barrera C Department of Parasitology Mycology, University Hospital of Besançon, UMR/CNRS 6249 Chrono-Environnement Research Team, University of Bourgogne- Franche-Comté, France.
- Mosbahi S Pediatric Surgery Department, Fattouma Bourguiba Hospital, Medical School, Monastir, Tunisia.
- Bellanger AP Department of Parasitology Mycology, University Hospital of Besançon, UMR/CNRS 6249 Chrono-Environnement Research Team, University of Bourgogne- Franche-Comté, France.
- Farhani R Pediatric Surgery Department, Fattouma Bourguiba Hospital, Medical School, Monastir, Tunisia.
- Ksia A Pediatric Surgery Department, Fattouma Bourguiba Hospital, Medical School, Monastir, Tunisia.
- Gottstein B Institute for Infectious Diseases, Faculty of Medicine, University of Bern, 3001, Bern, Switzerland.
- Nouri A Pediatric Surgery Department, Fattouma Bourguiba Hospital, Medical School, Monastir, Tunisia.
- Babba H Université de Monastir, Faculté de Pharmacie, Laboratoire de Parasitologie-Mycologie Médicale et Moléculaire, LR12ES08 Departement de Biologie clinique B, 5000, Monastir, Tunisie.
- Millon L Department of Parasitology Mycology, University Hospital of Besançon, UMR/CNRS 6249 Chrono-Environnement Research Team, University of Bourgogne- Franche-Comté, France.
- 2020-11-18
Published in:
- Parasite immunology. - 2020
English
AIMS
Following treatment, cystic echinococcosis (CE) exhibits a relatively high relapse rate. Here, we evaluated the value of soluble programmed death-1 (sPD-1), sPD-1 ligand (sPD-L1) and anti-recP29 antibody concentrations, as predictors of early surgical treatment outcome in young CE-affected patients.
METHODS AND RESULTS
This prospective study included 59 Tunisian children (177 plasmas ), where CE was surgically treated and monitored for 3 post-operative years. Based on CE post-surgical development, patients were clustered into a "No relapsed" CE (NRCE; n = 39) and a "Relapsed" CE (RCE; n = 20) group. Serum levels of sPD-1, sPD-L1 and anti-recP29 IgG were measured using ELISA. In the NRCE group, sPD-1, sPD-L1 and anti-recP29 IgG concentrations were significantly lower at D365 than at D30. By contrast, in the RCE group, no significant difference was observed between D0, D30 and D365.When considering individual variations, the probability to be "relapse-free" was 67% and 73% when anti-recP29 IgG and sPD-L1 level, respectively, decreased between D30 and D365. The probability to be "relapse-free" was 86% when the sPD-1 level decreased between D30 and D365 (p= 0.003; Chi-square test).
CONCLUSION
sPD-1 may be a useful biomaker for the early evaluation of surgical procedure efficacy in pediatric CE cases.
Following treatment, cystic echinococcosis (CE) exhibits a relatively high relapse rate. Here, we evaluated the value of soluble programmed death-1 (sPD-1), sPD-1 ligand (sPD-L1) and anti-recP29 antibody concentrations, as predictors of early surgical treatment outcome in young CE-affected patients.
METHODS AND RESULTS
This prospective study included 59 Tunisian children (177 plasmas ), where CE was surgically treated and monitored for 3 post-operative years. Based on CE post-surgical development, patients were clustered into a "No relapsed" CE (NRCE; n = 39) and a "Relapsed" CE (RCE; n = 20) group. Serum levels of sPD-1, sPD-L1 and anti-recP29 IgG were measured using ELISA. In the NRCE group, sPD-1, sPD-L1 and anti-recP29 IgG concentrations were significantly lower at D365 than at D30. By contrast, in the RCE group, no significant difference was observed between D0, D30 and D365.When considering individual variations, the probability to be "relapse-free" was 67% and 73% when anti-recP29 IgG and sPD-L1 level, respectively, decreased between D30 and D365. The probability to be "relapse-free" was 86% when the sPD-1 level decreased between D30 and D365 (p= 0.003; Chi-square test).
CONCLUSION
sPD-1 may be a useful biomaker for the early evaluation of surgical procedure efficacy in pediatric CE cases.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1111/pim.12809
- PMID 33207012
- Persistent URL
- https://sonar.ch/global/documents/285392
Statistics
Document views: 24
File downloads: